The use of hypomethylating agents in the treatment of hematologic malignancies

References

• Ting A H, McGarvey K M, Baylin S B. The cancer epigenome—components and functional correlates. Genes Dev 2006; 20: 3215–3231
   PubMed Web of Science ®Google Scholar
• Pfeifer G P. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 2000; 450: 155–166
   PubMed Web of Science ®Google Scholar
• Wong I H, Ng M H, Huang D P, Lee J C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000; 95: 1942–1949
   PubMed Web of Science ®Google Scholar
• Cameron E E, Baylin S B, Herman J G. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999; 94: 2445–2451
   PubMed Web of Science ®Google Scholar
• Szyf M, Pakneshan P, Rabbani S A. DNA methylation and breast cancer. Biochem Pharmacol 2004; 68: 1187–1197
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 2002; 25: 16–26
   PubMed Web of Science ®Google Scholar
• Chitambar C R, Libnoch J A, Matthaeus W G, Ash R C, Ritch P S, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991; 37: 100–104
   PubMed Web of Science ®Google Scholar
• Silverman L R, Holland J F, Weinberg R S, Alter B P, Davis R B, Ellison R R, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7(Suppl 1)21–29
   PubMed Web of Science ®Google Scholar
• Silverman L R, McKenzie D R, Peterson B L, Holland J F, Backstrom J T, Beach C L, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903
   PubMed Web of Science ®Google Scholar
• Gryn J, Zeigler Z R, Shadduck R K, Lister J, Raymond J M, Sbeitan I, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res 2002; 26: 893–897
   PubMed Web of Science ®Google Scholar
• Silverman L R, Demakos E P, Peterson B L, Kornblith A B, Holland J C, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440
   PubMed Web of Science ®Google Scholar
• Ruter B, Wijermans P W, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106: 1744–1750
   PubMed Web of Science ®Google Scholar
• Sudan N, Rossetti J M, Shadduck R K, Latsko J, Lech J A, Kaplan R B, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006; 107: 1839–1843
   PubMed Web of Science ®Google Scholar
• Lee E J, Hogge D E, Gallagher R, Schiffer C A. Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia 1990; 4: 835–838
   PubMed Web of Science ®Google Scholar
• Saiki J H, Bodey G P, Hewlett J S, Amare M, Morrison F S, Wilson H E, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer 1981; 47: 1739–1742
   PubMed Web of Science ®Google Scholar
• Case D C, Jr. 5-azacytidine in refractory acute leukemia. Oncology 1982; 39: 218–221
   PubMed Web of Science ®Google Scholar
• Vogler W R, Miller D S, Keller J W. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 1976; 48: 331–337
   PubMed Web of Science ®Google Scholar
• McCredie K B, Bodey G P, Burgess M A, Gutterman J U, Rodriguez V, Sullivan M P, et al. Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep 1973; 57: 319–323
   PubMedGoogle Scholar
• Karon M, Sieger L, Leimbrock S, Finklestein J Z, Nesbit M E, Swaney J J. 5-azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973; 42: 359–365
   PubMed Web of Science ®Google Scholar
• Wijermans P W, Krulder J W, Huijgens P C, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11(Suppl 1)S19–S23
   PubMedGoogle Scholar
• Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, et al. 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993; 7(Suppl 1)30–35
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956–962
   PubMed Web of Science ®Google Scholar
• Wijermans P W, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84(Suppl 13)9–17
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa J P, Rosenfeld C S, Bennett J M, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109: 265–273
   PubMed Web of Science ®Google Scholar
• Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713–717
   PubMed Web of Science ®Google Scholar
• Issa J P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2(Suppl 1)S24–S29
   PubMedGoogle Scholar
• Kantarjian H M, O'Brien S M, Keating M, Beran M, Estey E, Giralt S, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997; 11: 1617–1620
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Cortes J, Giles F J, Faderl S, Issa J P, et al. Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522–528
   PubMed Web of Science ®Google Scholar
• Petti M C, Mandelli F, Zagonel V, De Gregoris C, Merola M C, Latagliata R, et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993; 7(Suppl 1)36–41
   PubMed Web of Science ®Google Scholar
• Issa J P, Garcia-Manero G, Giles F J, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635–1640
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Attadia V, Bullian P L, Gattei V, Carbone A, et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4(Suppl 3)28–32
   PubMed Web of Science ®Google Scholar
• Kornblith A B, Herndon J E, II, Silverman L R, Demakos E P, Odchimar-Reissig R, Holland J F, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441–2452
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L S, Lee S L, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604–3608
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
   PubMed Web of Science ®Google Scholar
• Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001; 114: 349–357
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674
   PubMed Web of Science ®Google Scholar
• Cheson B D, Greenberg P L, Bennett J M, Lowenberg B, Wijermans P W, Nimer S D, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425
   PubMed Web of Science ®Google Scholar
• Oki Y, Aoki E, Issa J P. Decitabine—bedside to bench. Crit Rev Oncol Hematol 2007; 61: 140–152
   PubMed Web of Science ®Google Scholar
• Yang A S, Doshi K D, Choi S W, Mason J B, Mannari R K, Gharybian V, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503
   PubMed Web of Science ®Google Scholar
• Issa J P, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948–3956
   PubMed Web of Science ®Google Scholar
• Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005; 65: 7086–7090
   PubMed Web of Science ®Google Scholar
• Chim C S, Liang R, Kwong Y L. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002; 20: 167–176
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Nguyen T T, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957–2964
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 2003; 101: 4644–4646, discussion 4645 – 4646
   PubMed Web of Science ®Google Scholar
• Maslak P, Chanel S, Camacho L H, Soignet S, Pandolfi P P, Guernah I, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006; 20: 212–217
   PubMed Web of Science ®Google Scholar
• Gore S D, Baylin S, Sugar E, Carraway H, Miller C B, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361–6369
   PubMed Web of Science ®Google Scholar
• Richel D J, Colly L P, Kluin-Nelemans J C, Willemze R. The antileukaemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 1991; 64: 144–148
   PubMed Web of Science ®Google Scholar
• Winton E F, Hearn E B, Martelo O, Presant C A, Adler S, Vogler W R, et al. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. Cancer Treat Rep 1985; 69: 807–811
   PubMedGoogle Scholar
• Steuber C P, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1996; 14: 1521–1525
   PubMed Web of Science ®Google Scholar
• Kritz A D, Raptis G, Menendez-Botet C, Maslak P, Jakubowski A. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am J Hematol 1996; 51: 117–121
   PubMed Web of Science ®Google Scholar
• Schiffer C A, Anderson K, Coleman M, Cuttner J. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study. Cancer Treat Rep 1985; 69: 1027–1028
   PubMedGoogle Scholar
• Hakami N, Look A T, Steuber P C, Krischer J, Castleberry R, Harris R, et al. Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1987; 5: 1022–1025
   PubMed Web of Science ®Google Scholar
• Goldberg J, Gryn J, Raza A, Bennett J, Browman G, Bryant J, et al. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am J Hematol 1993; 43: 286–290
   PubMed Web of Science ®Google Scholar
• Dutcher J P, Eudey L, Wiernik P H, Paietta E, Bennett J M, Arlin Z, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6: 770–775
   PubMed Web of Science ®Google Scholar
• Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie E A, et al. A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997; 11(Suppl 1)S24–S27
   PubMed Web of Science ®Google Scholar
• de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003; 97: 1242–1247
   PubMed Web of Science ®Google Scholar
• Schwartsmann G, Fernandes M S, Schaan M D, Moschen M, Gerhardt L M, Di Leone L, et al. Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997; 11(Suppl 1)S28–S31
   Google Scholar
• Garcia-Manero G, Kantarjian H M, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian H M, Gharibyan V, Jones D, O'Brien S, Verstovsek S, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899–906
   PubMed Web of Science ®Google Scholar
• Gore S D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005; 2(Suppl 1)S30–S35
   PubMedGoogle Scholar
• Esteller M, Guo M, Moreno V, Peinado M A, Capella G, Galm O, et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002; 62: 5902–5905
   PubMed Web of Science ®Google Scholar
• Coyle T E, Bair A K, Stein C, Vajpayee N, Mehdi S, Wright J. Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?. Am J Hematol 2005; 78: 256–260
   PubMed Web of Science ®Google Scholar
• Narayan A, Ji W, Zhang X Y, Marrogi A, Graff J R, Baylin S B, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77: 833–838
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Jiang G, Woods C, Muller H M, Fiegl H, Goebel G, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004; 64: 4472–4480
   PubMed Web of Science ®Google Scholar